Search

Hematology 2.0: navigating the world of medical apps

Interview with Dr Alex Langridge, SpR, by Dr Nuno Borges, MBBS, MRes, on behalf of YoungEHA. Despite the controversy surrounding them, medical apps remain extremely popular and lucrative endeavors.

Read more

Position of EHA on Research Funding

 

The challenge
The cost of biomedical research is great, but the cost of disease is immense. An ageing population and expensive innovations in medicine put an increasing burden on already stressed healthcare budgets.

Read more

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more

Meet Robin Foà, our Volunteer of the Month

Can you tell us what you do for EHA and when you started?
I have been a member of EHA from its beginning and have participated in all EHA Congresses.

Read more

Meet Robin Foà, our Volunteer of the Month

Can you tell us what you do for EHA and when you started?
I have been a member of EHA from its beginning and have participated in all EHA Congresses.

Read more

Revision of the EU’s pharmaceutical legislation

Background on the reformIn April 2023, the European Commission (EC) published two proposals to revise the existing (and outdated) pharmaceutical legislation. This includes legislation on medicines for children and rare diseases.

Read more

Renew your membership

If you want to keep enjoying the benefits of EHA membership— from around-the-clock access to EHA Campus to discounts on EHA Congress registration—you'll need to renew your membership.

Read more